Opinion: A UN meeting on TB is at best a means to more important ends

Posted in: Healthcare system, Latest, TB, TB

On September 22 ministers, heads of state, and other officials from around the world will gather in New York for the second United Nations High-Level Meeting on TB. Yet, a few months ago it was not the governments these officials represent, but two philanthropies that stepped in to ensure arguably the most important TB trial of the decade has the funding needed to proceed. Marcus Low contrasts commitments made at the previous UN High-Level Meeting on TB with recent data on funding for TB research and asks what this tells us about the state of the global response to an age-old killer.

Opinion: A UN meeting on TB is at best a means to more important ends

Good and bad news about new TB vaccines

Posted in: Edition 10: Drug-resistant TB, Edition 7: TB, Healthcare system, Latest, TB, TB

While there are nine experimental tuberculosis (TB) vaccines in advanced trials, the vaccine pipeline beyond those nine prospects is relatively depleted. Adele Baleta reports on this and much more from the virtual Global TB Vaccine Forum held last week.

Analysis: We need to do for TB vaccines what we’ve done for COVID-19

Posted in: COVID-19, Latest, TB

It is little wonder that some TB vaccine researchers suffer from a rare syndrome that understandably threatens their mental health. Symptoms include frustration, impatience, irritability, seemingly inexplicable rage, and in the least resilient, despair. It’s called VJS or vaccine jealousy syndrome, writes Chris Bateman.

Analysis: We need to do for TB vaccines what we’ve done for COVID-19

In-depth: SA at cutting edge of TB vaccine research

Posted in: Latest, TB, TB

It is a hundred years since the BCG vaccine, the only registered vaccine proven to offer some protection against tuberculosis (TB), was first used in people. Now researchers in South Africa are at the forefront of clinical trials testing experimental new TB vaccines. Adele Baleta reports.